Pharmaceuticals

Outlook for Artificial Tears Market: Key Developments and Future Strategies to 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#How Large Is the Artificial Tears Market Expected to Be in 2029?#_x000D_

The market size of thyroid cancer medications has seen swift expansion in the previous years. It’s expected to escalate from $1.16 billion in 2024 to $1.32 billion in 2025, experiencing a compound annual growth rate (CAGR) of 13.6%. The rise during the historic timespan can be ascribed to the growing cases of thyroid cancer, advancements in medical studies, supportive regulatory settings, and escalating healthcare expenditure._x000D_

_x000D_

Anticipations of swift expansion are held for the thyroid cancer drugs market in the upcoming years, with projections forecasting growth to “$2.12 billion in 2029 with a compound annual growth rate (CAGR) of 12.6%.” Contributing factors to this projected growth during the forecast period include the rising incidences of the disease, an aging population, advances in precision medicine, the improvement of healthcare infrastructure, and a growing awareness leading to early detection. Notable market trends for the forecast period encompass personalized medicine, targeted and immune therapies, ongoing clinical trials and drug development, combined treatment approaches, treatments driven by biomarkers, and the implementation of telemedicine and remote monitoring._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2601&type=smp_x000D_

_x000D_

#What Are The Contributors To Demand In The Artificial Tears Market?#_x000D_

The expanding incidence of dry eye disease (DED) is anticipated to fuel the growth of the artificial tear market. Insufficient or poor quality tear production, resultant in eye irritation and discomfort, characterizes this condition. To supplement the natural tear production and provide moistening relief to dry eyes, artificial tears are used. For instance, a survey conducted in March 2022 by Macquarie University in Australia, involving 5000 participants, revealed that 13% (15 out of 120) of individuals aged above 50 exhibited clinical symptoms of dry eye disease. The severity of the symptoms varied with 8.2% classified as mild, 2.5% moderate, and 1.6% severe. Moreover, according to Eyes On Eyecare, a U.S.-based digital news source for ophthalmology, the use of prescription and in-office dry eye disease treatments rose from 5.8% in 2021 to 7.56% in 2022, with a significant surge in the use of prescription treatments like topical steroids, from 0.9% to 9.1% over the same timeframe. Consequently, the escalating incidence of dry eye disease, amplifies the growth of the artificial tear market._x000D_

_x000D_

The thyroid cancer drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types _x000D_

2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types _x000D_

3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users _x000D_

_x000D_

Subsegments:_x000D_

1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab _x000D_

2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib _x000D_

3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib _x000D_

4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin _x000D_

5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib _x000D_

6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab _x000D_

7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib _x000D_

8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab_x000D_

_x000D_

#Which Emerging Trends And Strategic Shifts Are Shaping The Artificial Tears Market?#_x000D_

There is a rising trend of using combination drugs for thyroid cancer treatment due to their increased effectiveness and cancer progression prevention. These drugs incorporate two or more active pharmaceutical ingredients (APIs) in each dosage, preventing drug resistance development and the proliferation of cancer cells. An example is the FDA-approved combination of dabrafenib (Tafinlar), which inhibits BRAF, and trametinib (Mekinist), a MEK inhibitor, explicitly used for anaplastic thyroid cancer treatment._x000D_

_x000D_

#Who Are The Top-Ranked Companies In The Artificial Tears Market Today?#_x000D_

Major companies operating in the thyroid cancer drugs market include Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline plc, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd._x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report_x000D_

_x000D_

#How Is Artificial Tears Market Adoption Varying Across Different Regions And Sectors?#_x000D_

North America was the largest region in the thyroid cancer drugs market in 20242. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2601&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_